New drug application 21-628, Certican (everolimus), for the proposed indication of prophylaxis of rejection in heart transplantation: report from the Cardiovascular and Renal Drugs Advisory Committee, US Food and Drug Administration, November 16, 2005, Rockville, Md.
Department of Medicine, University of Colorado Health Sciences Center, Denver, CO 80203, USA. will.hiatt@uchsc.edu
William R
WR
Hiatt
Steven E
SE
Nissen
D017277:Drug Approval; D000068338:Everolimus; D006084:Graft Rejection / Q000517:prevention & control*; D016027:Heart Transplantation / Q000379:methods*; D006801:Humans; D017387:Investigational New Drug Application; D016030:Kidney Transplantation / Q000379:methods; D011292:Premedication; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
D000068338:Everolimus; D020123:Sirolimus